EMN 2021 | New EMN risk stratification model for NDMM
Mattia D’Agostino, MD, University of Torino, Turin, Italy, gives a summary of the new risk stratification model, the R2-ISS, for newly diagnosed multiple myeloma (NDMM), developed by the European Myeloma Network (EMN). The new model is based on the Revised International Staging System (R-ISS) and uses an additive scoring system which evaluates each single baseline risk feature for it’s impact on risk, including 1q copy number alterations. Data from 15 European clinical trials was collected through the HARMONY platform, amounting to data from 7077 NDMM patients. HARMONY is a European public-private partnership focusing on hematologic malignancies with unmet medical needs. Validation in an independent cohort is planned. This interview took place during the 2021 EMN congress.
